What were Beta Drugs Ltd's latest quarterly results?
Beta Drugs Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +0.2% (turning around (inflection up))
- Revenue Growth YoY: +0.2%
- Operating Margin: 18.8% (stable)
Beta Drugs Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +66.8%Weak
In , Beta Drugs Ltd (Pharma - API) is outperforming Nifty 500 with +66.8% relative strength. Fundamentals: Weak.
Beta Drugs Ltd Key Facts
- PE Ratio
- 51.2x
- Market Cap
- ₹2,125 Cr
- PAT Growth YoY
- +0%
- Revenue Growth YoY
- +0%
- OPM
- 18.8%
- RS vs Nifty 500
- +66.8%
PE: Mid ContractionFalling Knife
What's Happening
🔻Earnings declining and PE falling — fundamentals deteriorating
💰Trading 76% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
+0%
Inflection Up
Revenue YoY
+0%
Inflection Up
Operating Margin
18.8%
+32 bps YoY
PE Ratio
51.2
Current Price
₹2,097
Fundamental Score
33/100
Weak
3Y PAT CAGR
+10%
Market Cap
2.1K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Beta Drugs Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +0% | +19% | Inflection Up |
| PAT (Net Profit) | +0% | +10% | Inflection Up |
| OPM | 18.8% | +32 bps | Stable |
Other Top Pharma - API Stocks Beating Nifty 500
Frequently Asked Questions: Beta Drugs Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Beta Drugs Ltd's profit growing or declining?
Beta Drugs Ltd's profit is growing with an turning around (inflection up) trend.
- PAT Growth YoY: +0.2% (latest quarter)
- PAT Growth QoQ: +6.2% (sequential)
- 3-Year PAT CAGR: +9.8%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Beta Drugs Ltd's revenue growth trend?
Beta Drugs Ltd's revenue growth trend is turning around (inflection up).
- Revenue Growth YoY: +0.2%
- Revenue Growth QoQ: +7.7% (sequential)
- 3-Year Revenue CAGR: +19.3%
How is Beta Drugs Ltd's operating margin trending?
Beta Drugs Ltd's operating margin is stable.
- Current OPM: 18.8%
- OPM Change YoY: +0.3% basis points
- OPM Change QoQ: -0.6% basis points
What is Beta Drugs Ltd's 3-year profit and revenue CAGR?
Beta Drugs Ltd's long-term compounding rates
- 3-Year Profit CAGR: +9.8%
- 3-Year Revenue CAGR: +19.3%
Is Beta Drugs Ltd's growth accelerating or decelerating?
Beta Drugs Ltd's earnings growth is turning around (inflection up) with mixed signals on a sequential basis.
- YoY Acceleration: +5.0% bps
- Sequential Acceleration: +36.5% bps
What is Beta Drugs Ltd's trailing twelve month (TTM) performance?
Beta Drugs Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹39 Cr
- TTM PAT Growth: -44.5% YoY
- TTM Revenue: ₹378 Cr
- TTM Revenue Growth: -32.8% YoY
- TTM Operating Margin: 19.4%
Is Beta Drugs Ltd overvalued or undervalued?
Beta Drugs Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 51.2x
- Price-to-Book: 8.7x
What is Beta Drugs Ltd's current PE ratio?
Beta Drugs Ltd's current PE ratio is 51.2x.
- Current PE: 51.2x
- Market Cap: 2.1K Cr
How does Beta Drugs Ltd's valuation compare to its history?
Beta Drugs Ltd's current PE is 51.2x.
- Current PE: 51.2x
- Valuation Assessment: Significantly Overvalued
What is Beta Drugs Ltd's price-to-book ratio?
Beta Drugs Ltd's price-to-book ratio is 8.7x.
- Price-to-Book (P/B): 8.7x
- Book Value per Share: ₹241
- Current Price: ₹2097
Is Beta Drugs Ltd a fundamentally strong company?
Beta Drugs Ltd is rated Weak with a fundamental score of 33.32/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +0.2% (10% weight)
- PAT Growth YoY: +0.2% (10% weight)
- PAT Growth QoQ: +6.2% (10% weight)
- Margins stable (10% weight)
Is Beta Drugs Ltd debt free?
Beta Drugs Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹148 Cr
What is Beta Drugs Ltd's return on equity (ROE) and ROCE?
Beta Drugs Ltd's return ratios over recent years
- FY2024: ROCE 33.0%
- FY2025: ROCE 27.0%
- FY2026: ROCE 19.0%
Is Beta Drugs Ltd's cash flow positive?
Beta Drugs Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹37 Cr
- Free Cash Flow (FCF): ₹-14 Cr
- CFO/PAT Ratio: 90% (strong cash conversion)
What is Beta Drugs Ltd's dividend yield?
Beta Drugs Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹2097
Who holds Beta Drugs Ltd shares — promoters, FII, DII?
Beta Drugs Ltd's shareholding pattern (May 2026)
- Promoters: 59.1%
- FII (Foreign): 3.0%
- DII (Domestic): 6.0%
- Public: 31.9%
Is promoter holding increasing or decreasing in Beta Drugs Ltd?
Beta Drugs Ltd's promoter holding has decreased recently.
- Current Promoter Holding: 59.1% (May 2026)
- Previous Quarter: 64.6% (Mar 2026)
- Change: -5.53% (decreasing — worth monitoring)
How long has Beta Drugs Ltd been outperforming Nifty 500?
Beta Drugs Ltd has been outperforming Nifty 500 for 2 consecutive weeks, indicating early-stage outperformance.
Is Beta Drugs Ltd a new momentum entry or an established outperformer?
Beta Drugs Ltd is an established outperformer with 2 weeks of consecutive Nifty 500 outperformance.
Is Beta Drugs Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Beta Drugs Ltd may be worth studying
- Earnings growing at +0.2% YoY
- Cash flow is positive — CFO ₹37 Cr
What is the investment thesis for Beta Drugs Ltd?
Beta Drugs Ltd investment thesis summary:
Risk Factors (Bear Case)
- Appears significantly overvalued
What is the future outlook for Beta Drugs Ltd?
Beta Drugs Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: turning around (inflection up)
- Margin Trend: stable
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.